PURPOSE: A case of choroidal neovascularization (CNV) secondary to Sorsby fundus dystrophy (SFD) treated with systemic bevacizumab (Avastin). METHODS: A 41-year-old woman presented with CNV secondary to SFD in her better eye. The patient received three initial infusions of bevacizumab at a dose of 5 mg/kg at 2 week intervals and one additional infusion because of CNV recurrence at the 7 month follow-up. RESULTS: At 16 month follow-up, visual acuity had improved from 20/50 at baseline to 20/25; optical coherence tomography and fluorescein angiography showed no evidence of CNV activity. CONCLUSION: Systemic bevacizumab seems to be a promising treatment option for CNV secondary to SFD.
PURPOSE: A case of choroidal neovascularization (CNV) secondary to Sorsby fundus dystrophy (SFD) treated with systemic bevacizumab (Avastin). METHODS: A 41-year-old woman presented with CNV secondary to SFD in her better eye. The patient received three initial infusions of bevacizumab at a dose of 5 mg/kg at 2 week intervals and one additional infusion because of CNV recurrence at the 7 month follow-up. RESULTS: At 16 month follow-up, visual acuity had improved from 20/50 at baseline to 20/25; optical coherence tomography and fluorescein angiography showed no evidence of CNV activity. CONCLUSION: Systemic bevacizumab seems to be a promising treatment option for CNV secondary to SFD.
Authors: Jian Hua Qi; Ganying Dai; Philip Luthert; Shyam Chaurasia; Joe Hollyfield; Bernhard H F Weber; Heidi Stöhr; Bela Anand-Apte Journal: J Biol Chem Date: 2009-05-28 Impact factor: 5.157